2.4 Excretion

Excretion of toxins

Excretion is how the body eliminates toxins and their metabolites after exposure. It's the final step in the toxicokinetic process, and it directly determines how long a substance stays in the body and at what concentration. Several organs contribute to excretion, including the kidneys, liver, lungs, skin, and mammary glands. The route a toxin takes out of the body depends largely on its physicochemical properties.

Mechanisms of excretion

Three main mechanisms move toxins out of cells and organs:

• Passive diffusion moves toxins down their concentration gradient without energy input. This is the primary mechanism for gases like oxygen and carbon dioxide crossing the alveolar membrane.
• Active transport uses energy-dependent carrier proteins to move toxins against their concentration gradient. Organic anion transporters (OATs) and organic cation transporters (OCTs) in the kidney tubules work this way.
• Facilitated diffusion relies on carrier proteins to move substances across membranes along their concentration gradient, but without energy expenditure. Glucose and amino acid transporters are classic examples.

The mechanism involved matters because it affects how quickly and completely a toxin can be cleared. Active transport, for instance, can achieve more complete removal since it isn't limited by concentration equilibrium.

Excretion via kidneys

The kidneys are the primary route for eliminating water-soluble toxins and metabolites. Renal excretion involves three processes:

1. Glomerular filtration filters small, unbound molecules from the blood into the renal tubule. Only the free (unbound) fraction of a toxin gets filtered.
2. Tubular secretion actively transports toxins from peritubular capillaries into the tubular lumen, using OATs and OCTs. This can remove even protein-bound toxins.
3. Tubular reabsorption moves substances back from the tubular lumen into the blood. Non-ionized, lipophilic compounds are more readily reabsorbed, which slows their excretion.

The net rate of renal excretion depends on blood flow to the kidneys, glomerular filtration rate (GFR), and the balance between secretion and reabsorption. Urine pH also plays a role: alkalinizing the urine keeps weak acids ionized in the tubule, reducing reabsorption and speeding excretion. This principle is used clinically (e.g., sodium bicarbonate administration for aspirin overdose).

Examples of toxins excreted primarily via the kidneys include heavy metals (cadmium, lead) and drugs like aminoglycosides and cisplatin.

Excretion via liver

The liver handles lipophilic toxins that can't be efficiently filtered by the kidneys. Hepatic excretion follows a two-part process:

1. Biotransformation by hepatic enzymes (primarily cytochrome P450 in Phase I) modifies the toxin's structure. Phase II conjugation reactions then attach polar molecules like glucuronic acid or sulfate, increasing water solubility.
2. Biliary excretion moves the conjugated metabolites into bile, which is secreted into the small intestine and ultimately eliminated in feces.

A key concept here is enterohepatic recirculation: some conjugated toxins are deconjugated by gut bacteria in the intestine, reabsorbed into the portal circulation, and returned to the liver. This recycling loop can significantly prolong a toxin's half-life. Morphine and benzo[a]pyrene both undergo enterohepatic recirculation.

Other examples of toxins excreted via the liver include acetaminophen metabolites and polycyclic aromatic hydrocarbons.

Excretion via lungs

The lungs excrete volatile toxins and gases through passive diffusion from pulmonary capillary blood into the alveoli, followed by exhalation. The rate of pulmonary excretion depends on:

• The blood:air partition coefficient (how readily the substance leaves blood for alveolar air)
• Alveolar ventilation rate
• Pulmonary blood flow

Substances with low blood solubility (like nitrous oxide) are exhaled quickly, while those with higher blood solubility (like chloroform) take longer. This is the same principle that makes breath alcohol testing possible: ethanol is partially excreted through the lungs at a predictable ratio to blood concentration.

Examples include organic solvents (toluene, xylene) and anesthetic gases (sevoflurane, nitrous oxide).

Excretion via skin

The skin provides a minor excretion route through sweat glands and sebaceous glands. Lipophilic toxins can partition into sweat or sebum and be eliminated at the skin surface.

While the overall contribution is small compared to renal or hepatic excretion, it can be toxicologically significant for certain substances. Heavy metals like arsenic and mercury are detectable in sweat, and this route has forensic relevance (e.g., hair and nail analysis for chronic arsenic exposure). Some drugs, including methadone and fentanyl, are also excreted in sweat at low levels.

Excretion via mammary glands

Toxins can be excreted in breast milk, creating a potential exposure pathway for nursing infants. Lipophilic compounds are of particular concern because breast milk has a high fat content (roughly 3-5%), which favors partitioning of fat-soluble substances.

Persistent organic pollutants like PCBs and dioxins accumulate in maternal fat stores and are mobilized into breast milk during lactation. Certain medications (some antidepressants, chemotherapeutic agents) also transfer into milk. This route is a significant consideration in risk assessment for lactating women, and infant exposure through breast milk can be substantial relative to the infant's small body weight.

Factors affecting excretion

Physicochemical properties of toxins

A toxin's molecular characteristics largely dictate its excretion route and rate:

• Lipophilicity: Lipophilic toxins accumulate in fatty tissues and are excreted more slowly. They tend to require hepatic biotransformation before they can be eliminated.
• Ionization: Ionized (charged) molecules are more water-soluble and more readily excreted by the kidneys. The Henderson-Hasselbalch equation predicts the degree of ionization based on the toxin's pKa and the pH of the surrounding fluid.
• Molecular weight: Compounds with molecular weights below roughly 500 Da are typically filtered by the glomerulus. Larger molecules are more likely to be excreted via bile.

These properties interact with each other. A small, ionized, water-soluble molecule will be cleared renally with relative ease, while a large, lipophilic, non-ionized compound may persist in the body for extended periods.

Protein binding of toxins

Many toxins bind to plasma proteins, particularly albumin (for acidic compounds) and alpha-1-acid glycoprotein (for basic compounds). Protein binding affects excretion because:

• Only the free (unbound) fraction is available for glomerular filtration
• Bound toxins cannot readily cross cell membranes
• Higher protein binding generally means slower excretion

The extent of binding varies by toxin and can be altered by the individual's protein levels (e.g., hypoalbuminemia in liver disease increases the free fraction). Competition for binding sites between two substances can displace one, suddenly increasing its free concentration and excretion rate, but also its availability to cause toxicity.

Biotransformation of toxins

Biotransformation directly influences excretion by changing a toxin's physicochemical properties:

• Phase I reactions (oxidation, reduction, hydrolysis) introduce or expose functional groups, which can increase or decrease water solubility depending on the specific reaction.
• Phase II reactions (conjugation with glucuronic acid, sulfate, glutathione, or amino acids) almost always increase water solubility, making the metabolite easier to excrete via kidneys or bile.

Genetic polymorphisms in biotransformation enzymes (e.g., CYP2D6 poor metabolizers vs. ultra-rapid metabolizers) create significant interindividual variation in how quickly toxins are converted and excreted.

Genetic variations in excretion

Beyond metabolic enzymes, genetic polymorphisms in transporter proteins also affect excretion:

• Variants in organic anion transporters (OATs) and organic cation transporters (OCTs) alter renal tubular secretion rates
• Polymorphisms in P-glycoprotein (encoded by the MDR1 gene) affect biliary and renal excretion of many substrates
• Variations in UDP-glucuronosyltransferases (UGTs) and glutathione S-transferases (GSTs) influence conjugation efficiency and biliary excretion

These genetic differences help explain why the same dose of a toxin can produce different effects in different people.

Age and excretion

Age significantly impacts excretion efficiency at both ends of the lifespan:

• Neonates and infants have immature renal function (low GFR, reduced tubular secretion) and underdeveloped hepatic enzyme systems. GFR doesn't reach adult levels until about 6-12 months of age. This means slower excretion and greater susceptibility to toxicity.
• Elderly individuals experience declining GFR (roughly 1 mL/min/year after age 40), reduced renal blood flow, and decreased hepatic mass and blood flow. Body composition also shifts toward higher fat percentage, which can increase the volume of distribution for lipophilic toxins and prolong their elimination.

Disease states and excretion

Disease can impair excretion through multiple organs:

• Renal disease (acute kidney injury, chronic kidney disease) reduces GFR and tubular function, slowing elimination of water-soluble toxins. Dose adjustments are often necessary.
• Hepatic disease (cirrhosis, hepatitis) impairs biotransformation and biliary excretion, causing lipophilic toxins to accumulate.
• Cardiovascular disease reduces blood flow to the kidneys and liver, decreasing the delivery of toxins to these excretory organs.
• Respiratory disease can impair pulmonary excretion of volatile substances by reducing alveolar surface area or ventilation.

Toxicokinetics of excretion

Absorption, distribution, metabolism, excretion (ADME)

Excretion is the final component of the ADME framework that describes a toxin's journey through the body:

1. Absorption: The toxin enters systemic circulation from the exposure site (GI tract, lungs, skin).
2. Distribution: The toxin is transported via blood to tissues and organs, influenced by blood flow, tissue affinity, and protein binding.
3. Metabolism: Biotransformation alters the toxin's structure, typically making it more polar and easier to excrete.
4. Excretion: The parent compound and/or metabolites are eliminated from the body.

These processes don't happen in strict sequence. Distribution, metabolism, and excretion often occur simultaneously, and the balance between them determines the toxin's concentration at target sites over time.

Elimination half-life of toxins

The elimination half-life ($t_{1/2}$) is the time required for the body's concentration of a toxin to decrease by 50%. It's calculated as:

$t_{1/2} = \frac{0.693 \times V_d}{CL}$

where $V_d$ is the volume of distribution and $CL$ is total clearance.

Half-lives vary enormously across substances:

• Nicotine: ~2 hours
• Ethanol: ~4-5 hours
• Lead (in blood): ~30 days
• Dioxins (TCDD): ~7-11 years

A practical rule: it takes approximately 5 half-lives to eliminate ~97% of a toxin from the body. Toxins with long half-lives are more prone to accumulation with repeated exposure.

Clearance of toxins

Clearance (CL) represents the volume of blood completely cleared of a toxin per unit time. It quantifies excretory efficiency.

Total clearance is the sum of organ-specific clearances:

$CL_{total} = CL_r + CL_h + CL_{other}$

Renal clearance can be calculated from urine data:

$CL_r = \frac{U \times V}{P}$

where $U$ is urine concentration of the toxin, $V$ is urine flow rate, and $P$ is plasma concentration.

Hepatic clearance depends on hepatic blood flow, the fraction unbound in plasma, and intrinsic clearance (the liver's inherent metabolic and excretory capacity). For high-extraction drugs, hepatic clearance is limited primarily by blood flow; for low-extraction drugs, it depends more on protein binding and enzyme activity.

Bioaccumulation of toxins

Bioaccumulation occurs when a toxin's rate of absorption exceeds its rate of excretion, causing the body burden to increase over time. Substances most prone to bioaccumulation are:

• Highly lipophilic (partition into fat stores)
• Resistant to biotransformation
• Slowly excreted

Biomagnification is a related concept where toxin concentrations increase at successively higher trophic levels in a food chain. Mercury in aquatic ecosystems is a classic example: methylmercury concentrations can be millions of times higher in top predators (e.g., tuna, swordfish) than in surrounding water.

The extent of bioaccumulation depends on the toxin's physicochemical properties, exposure duration and frequency, and the organism's metabolic and excretory capacity.

Excretion-related toxicities

Nephrotoxicity

Nephrotoxicity refers to kidney damage caused by toxins, which can in turn impair the kidney's own excretory function, creating a dangerous feedback loop. Mechanisms include:

• Vasoconstriction of renal blood vessels, reducing filtration (e.g., NSAIDs, cyclosporine)
• Direct tubular damage from toxic concentrations in tubular cells (e.g., aminoglycosides, cisplatin)
• Intratubular obstruction from crystal or cast formation (e.g., ethylene glycol metabolites)

Chronic nephrotoxin exposure can lead to glomerulosclerosis and progressive chronic kidney disease. Heavy metals like cadmium accumulate in the renal cortex and cause damage over years of low-level exposure. Aristolochic acid (found in some herbal remedies) is another notable nephrotoxin linked to Balkan endemic nephropathy.

Hepatotoxicity

Hepatotoxicity refers to liver damage from toxic substances, impairing the liver's capacity for biotransformation and biliary excretion. Mechanisms include:

• Oxidative stress and reactive metabolite formation (e.g., acetaminophen's toxic metabolite NAPQI)
• Mitochondrial dysfunction (e.g., valproic acid)
• Immune-mediated reactions (e.g., halothane hepatitis)

Chronic hepatotoxin exposure can progress through fibrosis to cirrhosis and liver failure. Aflatoxins (from Aspergillus mold contamination of food) are potent hepatotoxins and hepatocarcinogens. Alcohol remains one of the most common causes of hepatotoxicity worldwide.

Pulmonary toxicity

Pulmonary toxicity damages the lungs and can impair their ability to excrete volatile substances. Inhaled toxins can cause:

• Acute inflammation and alveolar-capillary barrier disruption
• Oxidative stress in lung tissue
• Fibrotic remodeling with chronic exposure

Cigarette smoke, asbestos fibers, and air pollutants (ozone, particulate matter $PM_{2.5}$) are major pulmonary toxins. Chronic exposure can lead to interstitial lung disease, pulmonary fibrosis, or respiratory failure.

Dermal toxicity

Dermal toxicity involves skin damage from toxic exposure. While the skin is a minor excretory organ, damage to it can alter barrier function and affect both absorption and excretion of substances. Effects range from:

• Acute irritation or corrosion (strong acids/bases, solvents)
• Allergic contact dermatitis (nickel, chromium, poison ivy urushiol)
• Chronic effects including skin sensitization and carcinogenesis (UV radiation, arsenic)

Methods to enhance excretion

In cases of poisoning or overdose, several clinical interventions can accelerate toxin removal.

Dialysis

Dialysis removes toxins from the blood using a semipermeable membrane.

• Hemodialysis circulates blood through an external dialyzer, effectively removing small, water-soluble, minimally protein-bound toxins. It's useful for methanol, ethylene glycol, lithium, and salicylate poisoning.
• Peritoneal dialysis uses the peritoneal membrane as a filter by instilling dialysate into the abdominal cavity. It's less efficient than hemodialysis but can be used when vascular access is unavailable.

Dialysis is not effective for large, lipophilic, or highly protein-bound toxins because these don't cross the dialysis membrane efficiently.

Hemoperfusion

Hemoperfusion passes blood through a cartridge containing an adsorbent material (typically activated charcoal or resin). The adsorbent binds toxins directly, removing them from circulation.

This technique can be more effective than dialysis for lipophilic or protein-bound toxins, since the adsorbent can strip toxins from protein binding sites. However, it also removes platelets and clotting factors, potentially causing thrombocytopenia or coagulopathy. Its clinical use has declined as dialysis technology has improved.

Chelation therapy

Chelation therapy uses chelating agents that bind metal ions to form stable, water-soluble complexes that are excreted in urine. Common chelating agents include:

• Dimercaprol (BAL): Used for arsenic, mercury, and gold poisoning
• EDTA (calcium disodium edetate): Used for lead poisoning
• Succimer (DMSA): An oral agent used for lead poisoning in children
• Penicillamine: Used for copper (Wilson's disease) and sometimes lead

The choice of agent depends on the specific metal, severity of poisoning, and route of administration. Close monitoring of renal function and essential mineral levels is required, as chelators can also bind and deplete essential metals like zinc.

Forced diuresis

Forced diuresis increases urine output through IV fluids and diuretics (furosemide, mannitol) to speed renal excretion of water-soluble toxins.

Alkaline diuresis (adding sodium bicarbonate to raise urine pH) is particularly effective for weak acids like salicylates and phenobarbital, because the alkaline urine keeps these compounds ionized in the tubule, preventing reabsorption.

Risks include electrolyte imbalances (hypokalemia, hypocalcemia), fluid overload, and pulmonary edema. Forced diuresis is only useful for toxins that are primarily eliminated unchanged in urine and is used less frequently now than in the past.

Excretion in risk assessment

Excretion data in toxicology studies

Excretion data are fundamental to understanding how quickly and completely a toxin leaves the body, which directly informs risk assessment.

• In vivo animal studies provide data on excretion routes, rates, and dose-dependent changes. Radiolabeled compounds allow tracking of the parent toxin and all metabolites across urine, feces, exhaled air, and tissues.
• In vitro studies using hepatocytes, kidney cell lines, or membrane vesicles help identify specific transporters and enzymes involved in excretion and can reveal species differences.
• Human clinical studies, when ethically feasible, provide the most directly relevant data. Biomonitoring studies measuring toxin levels in urine, blood, or breast milk also contribute valuable excretion information.

Excretion in physiologically based pharmacokinetic (PBPK) modeling

PBPK models are computational tools that integrate anatomical, physiological, and biochemical data to simulate the ADME of a substance in the body. Excretion parameters (renal clearance, biliary clearance, pulmonary exhalation rates) are critical model inputs.

These models can simulate how excretion changes under different conditions: varying doses, different exposure routes, altered organ function, or different life stages. PBPK models are increasingly used by regulatory agencies to extrapolate from animal data to human predictions and to account for population variability in excretion capacity.

Excretion in setting exposure limits

Excretion data inform the derivation of safe exposure limits such as acceptable daily intakes (ADIs) and tolerable daily intakes (TDIs):

• These limits are typically based on a NOAEL (no-observed-adverse-effect level) or BMD (benchmark dose) from animal studies, divided by uncertainty factors.
• Toxins with slower excretion rates may warrant larger uncertainty factors because they're more likely to accumulate with repeated exposure.
• Excretion data also guide the selection of biomarkers of exposure (e.g., urinary cadmium for chronic cadmium exposure, urinary cotinine for tobacco smoke exposure) used to monitor compliance with exposure limits.

Excretion in drug development

Excretion in drug design

Excretion pathways are considered early in drug design to optimize pharmacokinetics and minimize toxicity:

• Drugs can be engineered to favor specific excretion routes. For example, drugs targeting urinary tract infections may be designed for high renal excretion to achieve therapeutic concentrations at the site of action.
• Structural modifications can improve water solubility or reduce protein binding to enhance clearance.
• Prodrug strategies can be used where the administered compound is inactive but undergoes biotransformation to a more readily excreted active form.

Excretion in drug safety assessment

Excretion studies are required throughout preclinical and clinical drug development:

• In vitro assays using hepatocytes or renal proximal tubule cells screen for potential excretion-related toxicities and identify which transporters and enzymes are involved.
• In vivo animal studies characterize the mass balance (what percentage of the dose is recovered in urine, feces, and expired air) and identify major metabolites.
• Clinical pharmacokinetic studies in humans confirm excretion routes and rates, and special population studies (renal impairment, hepatic impairment, elderly) determine whether dose adjustments are needed.